

TREATMENT OF METASTATIC HER2+ BREAST CANCER: USE OF TRASTUZUMAB BIOSIMILARS IN COMBINATION WITH PERTUZUMAB

N. PAGNOTTA¹, E. REA¹, F. FERRANTE¹, D. MASTROIANNI¹, P. GAGLIARDI¹, M.L. MARZIALE¹, C. PAPETTI¹, R.M. FOLCARELLI¹.
¹ASL FROSINONE, UOC FARMACIA, FROSINONE, ITALY.
 uocfarmacia@aslfrosinone.it

SPSQ-092


Background and importance

Pertuzumab is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

The first biosimilars of trastuzumab were marketed in 2018.

Biosimilar medicines are safe and effective, provide a lower cost treatment option for the national health service, therefore, allow increased access to high cost therapies.


Aim and objectives




Cost-effectiveness comparison of pertuzumab+trastuzumab originator vs pertuzumab+trastuzumab biosimilar.

Evaluation of the efficacy and safety of treatment with biosimilar trastuzumab and economic impact.

Material and methods



Results



Conclusion and relevance

In clinical practice, treatment in combination with biosimilar trastuzumab has demonstrated efficacy and safety, with no increase in end-of-treatment for progression/toxicity/causes dependent on the biosimilar drug. The reduction in economic impact was significant.